<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8288D666-63BA-4F6B-8B3B-EDEB230048CB"><gtr:id>8288D666-63BA-4F6B-8B3B-EDEB230048CB</gtr:id><gtr:name>Genewerks</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E34F39A1-E98F-45E3-A8AF-57F7D0B7A942"><gtr:id>E34F39A1-E98F-45E3-A8AF-57F7D0B7A942</gtr:id><gtr:name>Necker-Enfants Malades Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15"><gtr:id>80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15</gtr:id><gtr:name>Ospedale San Raefaelle</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31C8C3D6-0F45-4639-8C94-78C0C503AB52"><gtr:id>31C8C3D6-0F45-4639-8C94-78C0C503AB52</gtr:id><gtr:name>Genethon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Child Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8288D666-63BA-4F6B-8B3B-EDEB230048CB"><gtr:id>8288D666-63BA-4F6B-8B3B-EDEB230048CB</gtr:id><gtr:name>Genewerks</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E34F39A1-E98F-45E3-A8AF-57F7D0B7A942"><gtr:id>E34F39A1-E98F-45E3-A8AF-57F7D0B7A942</gtr:id><gtr:name>Necker-Enfants Malades Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15"><gtr:id>80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15</gtr:id><gtr:name>Ospedale San Raefaelle</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31C8C3D6-0F45-4639-8C94-78C0C503AB52"><gtr:id>31C8C3D6-0F45-4639-8C94-78C0C503AB52</gtr:id><gtr:name>Genethon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F25BC0C5-5284-441F-B79F-A61707946CA0"><gtr:id>F25BC0C5-5284-441F-B79F-A61707946CA0</gtr:id><gtr:name>University of California Los Angeles</gtr:name><gtr:address><gtr:line1>405 Hillgard Avenue</gtr:line1><gtr:line2>Box 951361</gtr:line2><gtr:postCode>90095</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/32C75711-61FE-40B1-B099-73E64CC6EF27"><gtr:id>32C75711-61FE-40B1-B099-73E64CC6EF27</gtr:id><gtr:firstName>Hubert</gtr:firstName><gtr:otherNames>Baburaj</gtr:otherNames><gtr:surname>Gaspar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B0FFB06E-0C80-4114-9D30-7040F66F445B"><gtr:id>B0FFB06E-0C80-4114-9D30-7040F66F445B</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thrasher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802483"><gtr:id>1ED010C5-BF75-424A-905E-AC39A110408A</gtr:id><gtr:title>Development of a lentiviral vector for gene therapy of ADA deficiency</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802483</gtr:grantReference><gtr:abstractText>ADA deficiency is a severe form of immunodeficiency which leaves affected children very vulnerable to infections from all types of bacteria and viruses. Bone marrow transplant can correct the disease but carries with it major difficulties especially if a fuly matched donor is not available. For this reason, attempts to cure the disease by gene therapy have been developed. In initial trials, this has been very promising but the current methods by which the ADA gene is introduced into the child s cells may have potential problems for the future. We are now trying to develop safer ways of carrying genes into cells and in this project we aim to test whether these new methods are both effective and safe.</gtr:abstractText><gtr:technicalSummary>Adenosine deaminase (ADA) deficiency leads to severe combined immunodeficiency resulting in recurrent infections and death in the first year of life without definitive treatment. Gene therapy using gammaretroviral vector mediated correction of autologous haematopoietic stem cells (HSCs) has shown significant efficacy in correcting the immunological defects associated with ADA deficiency. However, the use of gammaretroviral vectors is complicated by their potential for insertional mutagenesis which has led to the development of leukaemia in patients treated by gene therapy for other immunodeficiencies. There is a pressing need to move to safer but equally efficacious vector strategies. Lentiviral vectors are able to transduce HSCs effectively but exhibit a significantly reduced potential for insertional mutagenesis. We have generated lentiviral vectors with the ADA gene under the transcriptional control of an internal mammalian promoter. We aim to demonstrate the efficacy and safety of this lentiviral vector in promoting immune and metabolic correction in cellular and animal models of ADA deficiency. These studies are critical before such vectors can be used in clinical studies.</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>564818</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Center for Chronic Immunodeficiency (CCI)</gtr:department><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>8912070B-B2AC-4FC8-A30A-3EE193F0B3A2</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-5</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale San Raefaelle</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>19BEA8E7-1E29-450A-8C91-E8D770E067FE</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-2</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>7ECD4ABA-851F-4210-ADE0-8F94C8007F60</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-3</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genewerks</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>4DA56936-33DC-4E71-8AC4-E85AA4304F49</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-7</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, Los Angeles (UCLA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Clinical trial</gtr:description><gtr:id>B93A1D6B-7656-442D-9DF9-13F8638AA7A6</gtr:id><gtr:impact>manuscripts</gtr:impact><gtr:outcomeId>5464b3d87ef8e2.12955547-1</gtr:outcomeId><gtr:partnerContribution>Partnership in a clinical trial development and a clinical trial</gtr:partnerContribution><gtr:piContribution>Partnership in a clinical trial development and a clinical trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genethon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>4F34AF9C-5CC5-4DFE-9BBD-4412B380B7E6</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-4</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Necker-Enfants Malades Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>DA5D9039-B450-4949-BCB6-3D534FD35F71</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-1</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hannover Medical School</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Experimental Hematology</gtr:department><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>4125E441-100F-4725-9B42-B7048E63555F</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-6</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D0A73598-2934-4EB1-AA01-EA4913C52328</gtr:id><gtr:impact>Lecturing at a patient awareness day

n/a</gtr:impact><gtr:outcomeId>6B08083224A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>84000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EC FP7 funding</gtr:description><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>3B0183D7-2717-42E8-A68D-D1FE91B51C64</gtr:id><gtr:outcomeId>A06BAEB09A20</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1472122</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Phase I/II trial of lentiviral vector mediated gene therapy for Adenosine Deaminase deficiency</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015427/1</gtr:fundingRef><gtr:id>9485A530-2F6C-4A58-A539-E453C9222FF5</gtr:id><gtr:outcomeId>MMx56nc3M2W</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6926317</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>EU H2020</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E722949F-FF99-4012-AE80-4242BE852C4E</gtr:id><gtr:outcomeId>56df02dc50cb33.34183212</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A lentiviral vector for the treatment of ADA SCID</gtr:description><gtr:grantRef>G0802483</gtr:grantRef><gtr:id>468DD1A1-DB55-4550-BC12-A2DADBF5B9FF</gtr:id><gtr:impact>Successful treatment of ADA SCID</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56df0530ab93f8.54014673</gtr:outcomeId><gtr:patentId>KEMP.P0052US.P1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>A lentiviral vector for the treatment of ADA SCID</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Orchard Therapeutics</gtr:companyName><gtr:description>Ex vivo bone marrow gene therapy company</gtr:description><gtr:id>58CEB6D5-2A64-4B0C-9F1C-6153EE020EA3</gtr:id><gtr:impact>none so far but intention to take gene therapy developments to licensed medicines</gtr:impact><gtr:outcomeId>56df05b29c8cf5.18525541</gtr:outcomeId><gtr:url>http://orchard-tx.com/</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>2C71457C-FA55-477B-90B7-20E1D3D68E29</gtr:id><gtr:title>Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e954465e7e4ad898168b5337d888000"><gtr:id>8e954465e7e4ad898168b5337d888000</gtr:id><gtr:otherNames>Carbonaro DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5464aa6019a922.73024145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63AB5A01-4A57-43D4-848E-5A8D348729F9</gtr:id><gtr:title>Gene therapy for ADA-SCID: defining the factors for successful outcome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd17b216b843d6a2bf8cc2768bf4e375"><gtr:id>dd17b216b843d6a2bf8cc2768bf4e375</gtr:id><gtr:otherNames>Gaspar HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13307_27_23118212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4C6DA7F-6DF7-40AC-BD35-50467E24F1C2</gtr:id><gtr:title>Current progress on gene therapy for primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/917fedf7d4ac4a5d4fbb9db6070723d7"><gtr:id>917fedf7d4ac4a5d4fbb9db6070723d7</gtr:id><gtr:otherNames>Zhang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_13307_27_23719067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EB0E364-7939-4C1B-BC65-8655210A0250</gtr:id><gtr:title>Gene therapy for primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389bb18dd04f9608cc69e03741418009"><gtr:id>389bb18dd04f9608cc69e03741418009</gtr:id><gtr:otherNames>Rivat C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>pm_13307_27_22691036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1821F9DF-CA69-4E27-AEF9-9CD62276207A</gtr:id><gtr:title>The ?-globin locus control region in combination with the EF1a short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6db97f40240b631583b97b0f14f1b744"><gtr:id>6db97f40240b631583b97b0f14f1b744</gtr:id><gtr:otherNames>Montiel-Equihua CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_13307_27_22434141</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802483</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>